Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Tislelizumab
How it works
Blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that tislelizumab can improve response rates and overall survival in patients with metastatic colorectal cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Tislelizumab Study for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Tislelizumab Efficacy in Lung Cancer Patients Similar Across Populations | Lung Cancer | phase-3 | Event-free survival (HR 0.56), major pathological response (OR 7.49), and pathological complete response (OR 11.54) were similar to predicted outcomes for European patients. | Source → |
| Long-term survival with tocilizumab treatment for tislelizumab-related pneumonitis | Lung Cancer | observational | — | Source → |
| Investigating Tislelizumab for Lung Cancer Treatment in European Patients | Lung Cancer | preclinical | — | Source → |
| Testing HFB200603 Alone and With Tislelizumab in Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Tislelizumab Improves Outcomes in Advanced Lung Cancer | Lung Cancer | phase-3 | The median overall survival was 16.9 months versus 11.9 months for tislelizumab versus docetaxel in the ITT population. | Source → |
| New Lung Cancer Treatment Shows Promise in Early Study | Lung Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Tislelizumab with Chemotherapy and Radiotherapy in Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Treatments for First-Line Squamous Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing LDRT with Immunochemotherapy for Colorectal Cancer with Liver Metastasis | Colorectal Cancer | phase-1 | — | Source → |
| Testing Fruquintinib and Tislelizumab in Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Real-World Study on Lung Cancer Treatment with Tislelizumab | Lung Cancer | preclinical | — | Source → |
| Combination Therapy Shows Promise for Rare Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 55.17% (95% CI, 35.69% - 73.55%). | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Melanoma | phase-1 | — | Source → |
| Testing Tislelizumab in Combination for Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Tislelizumab plus chemotherapy improves survival in advanced lung cancer | Lung Cancer | phase-3 | Median overall survival was 26.1 months in patients who received tislelizumab plus paclitaxel/carboplatin. | Source → |
| Rectal Cancer Trial Testing Chemotherapy, Radiation, and Immunotherapy | Colorectal Cancer | phase-2 | — | Source → |
| Cost-effectiveness of tislelizumab for lung cancer treatment in China | Lung Cancer | phase-3 | — | Source → |
| Combining Radiation and Immunotherapy for Advanced Rectal Cancer | Colorectal Cancer | phase-2 | The pathological complete response rate was 45.3% in the SCRT-TNT-ICI group compared to 27.6% in the SCRT-TNT group. | Source → |
| Tislelizumab Shows Promise in Lung Cancer Treatment | Lung Cancer | phase-3 | Tislelizumab significantly improved overall survival (hazard ratios: 0.72, 95% CI: 0.63-0.81) and progression-free survival (hazard ratios: 0.61, 95% CI: 0.54-0.68) compared to control treatments. | Source → |
| Cost-effectiveness of tislelizumab plus chemotherapy for lung cancer | Lung Cancer | phase-3 | The addition of tislelizumab to chemotherapy provided an incremental gain of 0.16 QALYs at an additional cost of $7430.73 in China, and 0.28 QALYs at an additional cost of $45,157.35 in the US. | Source → |
| Tislelizumab's Unique Binding to PD-1 May Improve Cancer Treatment | Melanoma | lab-study | — | Source → |
| New Form of Cancer Treatment May Be Easier to Use | Lung Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.